Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study With Temsirolimus Versus no add-on in Patients With Castration Resistant Prostate Cancer (CRPC) Receiving First-line Docetaxel Chemotherapy

NCT01206036 is registered in ClinicalTrials.gov with Central European Society for Anticancer Drug Research as lead sponsor.

NCT NCT01206036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01206036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study With Temsirolimus Versus no add-on in Patients With Castration Resistant Prostate Cancer (CRPC) Receiving First-line Docetaxel Chemotherapy
Lead sponsor
Central European Society for Anticancer Drug Research
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2010
Completion date
October 31, 2015
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms